| Issue Date | Title | Author(s) | Relation | scopus | WOS | Fulltext/Archive link |
| 2017 | Identification of MALT1 as both a prognostic factor and a potential therapeutic target of regorafenib in cholangiocarcinoma patients | Yeh, CN; Chang, YC; Su, Y; Hsu, DS; Cheng, CT; Wu, RC; Chung, YH; Chiang, KC; Yeh, TS; Lu, ML; Liu, CY; Chang, PM; Chen, MH; Huang, CY; Hsiao, M ; Chen, MH | Oncotarget 8(69), 113444-113459 | | | |
| 2017 | MART-10 represses cholangiocarcinoma cell growth and high vitamin D receptor expression indicates better prognosis for cholangiocarcinoma | Chiang, KC; Yeh, TS; Huang, CC; Chang, YC; Juang, HH; Chang, CT; Pang, JH; Chang, JT; Takano, M; Chen, TC; Kittaka, A; Hsiao, M ; Yeh, CN | Scientific Reports 7, 43773 | | | |
| 2020 | Omics-based Platforms: Current Status and Potential Use for Cholangiocarcinoma | Chang, YC; Chen, MH; Yeh, CN; Hsiao, M | Biomolecules 10(10), 1377 | | | |
| 2019 | Over-expression of TNNI3K is associated with early-stage carcinogenesis of cholangiocarcinom | Yeh, CN; Chen, MH; Chang, YC; Wu, RC; Tsao, LC; Wang, SY; Cheng, CT; Chiang, KC; Chen, TW; Hsiao, M ; Weng, WH | Molecular Carcinogenesis 58(2), 270-278 | | | |
| 2016 | Prenatal diagnosis of the maternal derivative chromosome der(15)t(Y;15)(q12;p13) in a dizygotic twin pregnancy. | Chen, PY; Yen, JH; Cheng, CF ; Chen, PC; Li, YS; Li, TY; Yeh, CN; Fang, JS | Tzu-chi medical journal(Ci ji yi xue za zhi) 28(4), 176-179 | | | |
| 2020 | PRKDC: A New Biomarker and drug target for Checkpoint Blockade Immunotherapy | Tan, KT; Yeh, CN; Chang, YC; Cheng, JH; Fang, WL; Yeh, YC; Hsu, DS; Wu, CE; Liu, CY; Chang, MS; Lu, ML; Chen, SJ; Yee, C; Hsiao, M ; Chen, MH | Journal for ImmunoTherapy of Cancer 8(1), e000485 | | | |
| 2021 | Proteomics-based identification of TMED9 is linked to vascular invasion and poor prognoses in patients with hepatocellular carcinoma | Yang, YC; Chien, MH; Lai, TC; Tung, MC; Jan, YH; Chang, WM; Jung, SM; Chen, MH; Yeh, CN; Hsiao, M | JOURNAL OF BIOMEDICAL SCIENCE 28, 29 | | | |
| 2022 | Regorafenib inhibits epithelial-mesenchymal transition and suppresses cholangiocarcinoma metastasis via YAP1-AREG axis | Chang, YC; Li, CH; Chan, MH; Yeh, CN; Chen, MH; Hsiao, M | CELL DEATH & DISEASE 13, 391 | | | |
| 2021 | Ruxolitinib Combined with Gemcitabine against Cholangiocarcinoma Growth via the JAK2/STAT1/3/ALDH1A3 Pathway | Chung, SY; Hung, YP; Pan, YR; Chang, YC; Wu, CE; Hsu, DS; Chang, PM; Lu, ML; Huang, CY; Su, Y; Hsiao, M ; Yeh, CN; Chen, MH | BIOMEDICINES 9(8), 885 | | | |
